August 8, 2007 – Mindray Medical, based in Shenzhen but listed on the NYSE, reported second-quarter earnings per share that were 20% above analysts estimates. Its net for the period represented a 69% increase over the year-earlier quarter, with sales to international markets leading the surge. Management raised its forecast slightly for full-year net income to 615 million RMB ($85 million), a number that seems conservative. Investors liked the positive report, sending the stock to an all-time high. The stock responded by climbing 14%, rising $4.19 to close at an all-time high of $35.17. More details...
